%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Sen Kwek, S.
%A Watanabe, S.
%A Chan, K. R.
%A Ong, E. Z.
%A Tan, H. C.
%A Ng, W. C.
%A Nguyen, M. T. X.
%A Gan, E. S.
%A Zhang, S. L.
%A Chan, K. W. K.
%A Tan, J. H.
%A Sessions, O. M.
%A Manuel, M.
%A Pompon, Julien
%A Chua, C.
%A Hazirah, S.
%A Tryggvason, K.
%A Vasudevan, S. G.
%A Ooi, E. E.
%T A systematic approach to the development of a safe live attenuated Zika vaccine
%D 2018
%L fdi:010072485
%G ENG
%J Nature Communications
%@ 2041-1723
%M ISI:000427121700006
%P art. 1031 [13 ]
%R 10.1038/s41467-018-03337-2
%U https://www.documentation.ird.fr/hor/fdi:010072485
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers18-04/010072485.pdf
%V 9
%W Horizon (IRD)
%X Zika virus (ZIKV) is a flavivirus that can cause congenital disease and requires development of an effective long-term preventative strategy. A replicative ZIKV vaccine with properties similar to the yellow fever 17D (YF17D) live-attenuated vaccine (LAV) would be advantageous, as a single dose of YF17D produces lifelong immunity. However, a replicative ZIKV vaccine must also be safe from causing persistent organ infections. Here we report an approach to ZIKV LAV development. We identify a ZIKV variant that produces small plaques due to interferon (IFN)-restricted viral propagation and displays attenuated infection of endothelial cells. We show that these properties collectively reduce the risk of organ infections and vertical transmission in a mouse model but remain sufficiently immunogenic to prevent wild-type ZIKV infection. Our findings suggest a strategy for the development of a safe but efficacious ZIKV LAV.
%$ 052 ; 050